Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single-dose open-label study of CSL889 in adults with sickle cell disease
NL-OMON52183Active, not recruiting
- Sponsor
- CSL Behring
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of hemopexin, sponsored by CSL Behring. Started Jun 2021; status: active, not recruiting.
02
Drugs
hemopexin
Beyond the preview
Go deeper on NL-OMON52183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52183.